Compounds > 1,3-cyclopentadiene
Page last updated: 2024-09-21

1,3-cyclopentadiene

Description

1,3-cyclopentadiene: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID7612
CHEMBL ID3188826
CHEBI ID30664
MeSH IDM0045852

Synonyms (35)

Synonym
cyclopentadiene
einecs 208-835-4
r-pentine
hsdb 2514
pyropentylene
pentole
542-92-7
CHEBI:30664 ,
1,3-cyclopentadiene
inchi=1/c5h6/c1-2-4-5-3-1/h1-4h,5h
cyclopenta-1,3-diene
GHL.PD_MITSCHER_LEG0.1205
FT-0656719
FT-0659414
dtxcid007191
cas-542-92-7
NCGC00255341-01
tox21_302134
dtxsid0027191 ,
A818675
26912-33-4
unii-5dfh9434hf
5dfh9434hf ,
ec 208-835-4
AKOS025295445
cyclopentadiene [mi]
1,3-cyclopentadiene [hsdb]
cyclo pentadiene
cyclopentadien
cyclo-pentadiene
CHEMBL3188826
Q424390
Q2209035
1.3-cyclopentadiene pound dimer form pound(c)
AT31522

Drug Classes (1)

ClassDescription
cycloalkadieneAn unsaturated monocyclic hydrocarbon having two endocyclic double bonds.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (2)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency61.13060.003041.611522,387.1992AID1159552
farnesoid X nuclear receptorHomo sapiens (human)Potency21.87240.375827.485161.6524AID743220
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (11)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (9.09)18.7374
1990's2 (18.18)18.2507
2000's4 (36.36)29.6817
2010's4 (36.36)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (9.09%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other10 (90.91%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceDescriptionRelationhip StrengthStudiesTrialsClassesRoles
quinone[no description available]medium101,4-benzoquinonescofactor;
human xenobiotic metabolite;
mouse metabolite
cyclopentane[no description available]medium110cycloalkane;
cyclopentanes;
volatile organic compound		non-polar solvent
dinoprostone[no description available]medium10prostaglandins Ehuman metabolite;
mouse metabolite;
oxytocic
pyrroles[no description available]medium10pyrrole;
secondary amine
furan[no description available]medium10furans;
mancude organic heteromonocyclic parent;
monocyclic heteroarene		carcinogenic agent;
hepatotoxic agent;
Maillard reaction product
hydrogen[no description available]medium10elemental hydrogen;
elemental molecule;
gas molecular entity		antioxidant;
electron donor;
food packaging gas;
fuel;
human metabolite
thiophenes[no description available]medium10mancude organic heteromonocyclic parent;
monocyclic heteroarene;
thiophenes;
volatile organic compound		non-polar solvent
2-cyclohexen-1-one[no description available]medium10cyclohexenone
tiletamine hydrochloride[no description available]medium10
phenoxy radical[no description available]medium10organic radical
dimethyl sulfoxide[no description available]medium10sulfoxide;
volatile organic compound		alkylating agent;
antidote;
Escherichia coli metabolite;
geroprotector;
MRI contrast agent;
non-narcotic analgesic;
polar aprotic solvent;
radical scavenger
ConditionIndicatedRelationship StrengthStudiesTrials
Adjuvant Arthritis0low10
Arthritis, Adjuvant0low10
Arthritis, Adjuvant-Induced0low10
Arthritis, Collagen-Induced0low10
Arthritis, Experimental0low10
Arthritis, Rheumatoid0low10
Collagen Arthritis0low10
Disease Models, Animal0low10
Inflammation0low20
Innate Inflammatory Response0low20
Rheumatoid Arthritis0low10

Research Highlights

Bioavailability (1)

ArticleYear
META060 inhibits multiple kinases in the NF-kappaB pathway and suppresses LPS--mediated inflammation in vitro and ex vivo.
Inflammation research : official journal of the European Histamine Research Society ... [et al.], Volume: 58, Issue: 5		2009
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]